7L1V image
Entry Detail
PDB ID:
7L1V
EMDB ID:
Title:
Orexin Receptor 2 (OX2R) in Complex with G Protein and Small-Molecule Agonist Compound 1
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2020-12-15
Release Date:
2021-02-10
Method Details:
Experimental Method:
Resolution:
3.00 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Engineered Guanine nucleotide-binding protein subunit alpha
Chain IDs:A
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:B
Chain Length:349
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:C
Chain Length:71
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:single-chain antibody Fv fragment (svFv16)
Chain IDs:D (auth: H)
Chain Length:250
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:Hypocretin receptor type 2
Chain IDs:E (auth: R)
Chain Length:374
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Synthetic nanobody 51 (Sb51)
Chain IDs:F (auth: S)
Chain Length:118
Number of Molecules:1
Biological Source:Lama glama
Ligand Molecules
Primary Citation
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation.
Nat Commun 12 815 815 (2021)
PMID: 33547286 DOI: 10.1038/s41467-021-21087-6

Abstact

Narcolepsy type 1 (NT1) is a chronic neurological disorder that impairs the brain's ability to control sleep-wake cycles. Current therapies are limited to the management of symptoms with modest effectiveness and substantial adverse effects. Agonists of the orexin receptor 2 (OX2R) have shown promise as novel therapeutics that directly target the pathophysiology of the disease. However, identification of drug-like OX2R agonists has proven difficult. Here we report cryo-electron microscopy structures of active-state OX2R bound to an endogenous peptide agonist and a small-molecule agonist. The extended carboxy-terminal segment of the peptide reaches into the core of OX2R to stabilize an active conformation, while the small-molecule agonist binds deep inside the orthosteric pocket, making similar key interactions. Comparison with antagonist-bound OX2R suggests a molecular mechanism that rationalizes both receptor activation and inhibition. Our results enable structure-based discovery of therapeutic orexin agonists for the treatment of NT1 and other hypersomnia disorders.

Legend

Protein

Chemical

Disease

Primary Citation of related structures